The FDA identified a recall of smartphone apps for Dexcom (Nasdaq:DXCM) continuous glucose monitors as the most serious type.

Dexcom (Nasdaq:DXCM) today announced plans to unveil its Smart Basal integrated titration module for insulin delivery.

At Dexcom (Nasdaq:DXCM), one of the leaders in continuous glucose monitoring (CGM), innovation continues to roll on.

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of ...

The new AI-powered Smart Food Logging feature supports greater personalized insights into how meals are impacting glucose levels Users can now take a photo of their food in their Stelo or Dexcom G7 ...

(Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence ...

DexCom, Inc. ( NASDAQ: DXCM) Baird Global Healthcare Conference 2025 September 10, 2025 2:00 PM EDT Next presentation this afternoon is from DexCom, a leader in developing and commercializing ...

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...

In partnership with data partner Plant A, Newsweek ranks America's Greatest Companies, where health care-related companies shine.